mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for CDKL3
Gene summary
Basic gene Info.Gene symbolCDKL3
Gene namecyclin-dependent kinase-like 3
CytomapUCSC genome browser: 5q31
Type of geneprotein-coding
Descriptionserine-threonine protein kinase NKIAMREserine/threonine-protein kinase NKIAMRE
Modification date20141207
dbXrefs MIM : 608459
Ensembl : ENSG00000006837
Vega : OTTHUMG00000186341
ProteinUniProt: Q8IVW4
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_CDKL3
BioGPS: 51265
PathwayNCI Pathway Interaction Database: CDKL3
Pathway Commons: CDKL3
ContextiHOP: CDKL3
ligand binding site mutation search in PubMed: CDKL3
UCL Cancer Institute: CDKL3
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez

Ligand binding site mutations for CDKL3
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for CDKL3
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for CDKL3 from PDB

Differential gene expression and gene-gene network for CDKL3
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of CDKL3 and the right PPI network was created from samples without mutations in the LBS of CDKL3. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for CDKL3
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for CDKL3
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of CDKL3 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of CDKL3
Multiple alignments for Q8IVW4 in multiple species
LBSAA sequence# speciesSpecies
A31TGRIVAIKIFY2Mus musculus, Rattus norvegicus
A31TGQIVAIKIFY1Homo sapiens
C142GITKLCDFGFA3Homo sapiens, Mus musculus, Rattus norvegicus
D143ITKLCDFGFAR3Homo sapiens, Mus musculus, Rattus norvegicus
D175ELVLKDTSYGK2Homo sapiens, Mus musculus
D175ELVLKDTTYGK1Rattus norvegicus
D83VFEFIDHTVLD3Homo sapiens, Mus musculus, Rattus norvegicus
D88DHTVLDELQHY3Homo sapiens, Mus musculus, Rattus norvegicus
E129RDIKPENILVS3Homo sapiens, Mus musculus, Rattus norvegicus
E80IHLVFEFIDHT3Homo sapiens, Mus musculus, Rattus norvegicus
F79KIHLVFEFIDH3Homo sapiens, Mus musculus, Rattus norvegicus
F81HLVFEFIDHTV3Homo sapiens, Mus musculus, Rattus norvegicus
H223GNLTPHLHNIF2Mus musculus, Rattus norvegicus
H223GNLSPHLQNIF1Homo sapiens
H84FEFIDHTVLDE3Homo sapiens, Mus musculus, Rattus norvegicus
I82LVFEFIDHTVL3Homo sapiens, Mus musculus, Rattus norvegicus
L132KPENILVSQSG3Homo sapiens, Mus musculus, Rattus norvegicus
N130DIKPENILVSQ3Homo sapiens, Mus musculus, Rattus norvegicus
T85EFIDHTVLDEL3Homo sapiens, Mus musculus, Rattus norvegicus
V10ETLGKVGEGSY3Homo sapiens, Mus musculus, Rattus norvegicus
V18GSYGTVMKCKH3Homo sapiens, Mus musculus, Rattus norvegicus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas